First‐in‐human phase 1 study of MK‐1248, an anti–glucocorticoid‐induced tumor necrosis factor receptor agonist monoclonal antibody, as monotherapy or with pembrolizumab in patients with advanced solid tumors

Background Ligation of glucocorticoid‐induced tumor necrosis factor receptor (GITR) decreases regulatory T cell–mediated suppression and enhances T‐cell proliferation, effector function, and survival. MK‐1248 is a humanized immunoglobulin G4 anti‐GITR monoclonal antibody agonist. Methods In patients...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Cancer 2020-11, Vol.126 (22), p.4926-4935
Hauptverfasser:	Geva, Ravit, Voskoboynik, Mark, Dobrenkov, Konstantin, Mayawala, Kapil, Gwo, Jennifer, Wnek, Richard, Chartash, Elliot, Long, Georgina V.
Format:	Artikel
Sprache:	eng
Schlagworte:	Agonists Anemia Antitumor activity Appetite loss Cancer carcinoma Cell proliferation Colorectal cancer Colorectal carcinoma Disease control Fatalities Glucocorticoids glucocorticoid‐induced tumor necrosis factor receptor (GITR) Immunoglobulin G4 Immunotherapy Kidney cancer Lymphocytes Lymphocytes T Melanoma Monoclonal antibodies Oncology Pembrolizumab Pharmacodynamics Pharmacokinetics Pharmacology Receptors Renal cell carcinoma Solid tumors Targeted cancer therapy Therapy Toxicity Tumor necrosis factor tumor necrosis factor receptor Tumor necrosis factor-TNF Tumors Vomiting
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!